Literature DB >> 26641076

Association between Hyaluronic Acid Injections and Time-to-Total Knee Replacement Surgery.

Roy Altman1, Michael Fredericson2, Samir K Bhattacharyya3, Brad Bisson3, Thomas Abbott4, Sashidhar Yadalam5, Myoung Kim5.   

Abstract

This study assessed the association between hyaluronic acid (HA) injections and time-to-total knee replacement (TKR) surgery for patients with knee osteoarthritis (OA). Patients 18 to 64 years of age who had TKR surgery between January 1, 2006 and December 31, 2011 were identified from the MarketScan Commercial claims database. All patients had 6 years or more of continuous enrollment prior to TKR surgery. There were two cohorts (1) patients with HA injections prior to TKR surgery and (2) patients who did not have HA injections prior to TKR surgery. Time-to-TKR was defined as the total days from the date of diagnosis of knee OA on the patient's first visit to an orthopedic surgeon to the date of TKR surgery. Results included 22,555 patients who had TKR surgery: 14,132 in the non-HA and 8,423 in the HA cohort. In this retrospective analysis of patients undergoing TKR, the median Time-to-TKR surgery was 326 days for the non-HA and 908 days for the HA cohort, a difference of 582 days. Those receiving HA injections had a median 1.6-year longer Time-to-TKR surgery versus those who did not receive HA injections. These results have both clinical and economic implications. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26641076     DOI: 10.1055/s-0035-1568992

Source DB:  PubMed          Journal:  J Knee Surg        ISSN: 1538-8506            Impact factor:   2.757


  21 in total

1.  Platelet-rich plasma injections delay the need for knee arthroplasty: a retrospective study and survival analysis.

Authors:  Mikel Sánchez; Cristina Jorquera; Pello Sánchez; Maider Beitia; Beatriz García-Cano; Jorge Guadilla; Diego Delgado
Journal:  Int Orthop       Date:  2020-07-03       Impact factor: 3.075

2.  EUROVISCO Guidelines for the Design and Conduct of Clinical Trials Assessing the Disease-Modifying Effect of Knee Viscosupplementation.

Authors:  Yves Henrotin; Xavier Chevalier; Raghu Raman; Pascal Richette; Jordi Montfort; Jörg Jerosch; Dominique Baron; Hervé Bard; Yannick Carrillon; Alberto Migliore; Thierry Conrozier
Journal:  Cartilage       Date:  2018-07-04       Impact factor: 4.634

3.  Hyaluronic acid injections for osteoarthritis of the knee: predictors of successful treatment.

Authors:  Eric N Bowman; Justin D Hallock; Thomas W Throckmorton; Fredrick M Azar
Journal:  Int Orthop       Date:  2018-01-03       Impact factor: 3.075

Review 4.  Osteoarthritis year in review 2017: clinical.

Authors:  A E Nelson
Journal:  Osteoarthritis Cartilage       Date:  2017-12-08       Impact factor: 6.576

5.  EUROVISCO Recommendations for Optimizing the Clinical Results of Viscosupplementation in Osteoarthritis.

Authors:  Thierry Conrozier; Jordi Monfort; Xavier Chevalier; Raghu Raman; Pascal Richette; Demirhan Diraçoglù; Hervé Bard; Dominique Baron; Jörg Jerosch; Alberto Migliore; Yves Henrotin
Journal:  Cartilage       Date:  2018-06-21       Impact factor: 4.634

6.  Safety of Repeated Injections of Sodium Hyaluronate (SUPARTZ) for Knee Osteoarthritis: A Systematic Review and Meta-Analysis.

Authors:  Raveendhara R Bannuru; Christopher R Brodie; Matthew C Sullivan; Timothy E McAlindon
Journal:  Cartilage       Date:  2016-04-11       Impact factor: 4.634

7.  Knee Osteoarthritis Treatment Costs in the Medicare Patient Population.

Authors:  Gerard Malanga; Faizan Niazi; Vasco Deon Kidd; Edmund Lau; Steven M Kurtz; Kevin L Ong; Andrew L Concoff
Journal:  Am Health Drug Benefits       Date:  2020-09

8.  A Malaysian Delphi consensus on managing knee osteoarthritis.

Authors:  Swan Sim Yeap; Syamsul Rizal Abu Amin; Hazlyna Baharuddin; Kar Chai Koh; Joon Kiong Lee; Verna Kar Mun Lee; Nor Hamdan Mohamad Yahaya; Cheh Chin Tai; Maw Pin Tan
Journal:  BMC Musculoskelet Disord       Date:  2021-06-04       Impact factor: 2.362

Review 9.  Viscosupplementation for the treatment of osteoarthritis. The contribution of EUROVISCO group.

Authors:  Thierry Conrozier; Raghu Raman; Xavier Chevalier; Yves Henrotin; Jordi Monfort; Demirhan Diraçoglù; Hervé Bard; Dominique Baron; Jörg Jerosch; Pascal Richette; Alberto Migliore
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-05-28       Impact factor: 5.346

10.  Important Considerations When Determining the Cost-effectiveness of Viscosupplements in the Treatment of Knee Osteoarthritis: Letter to the Editor regarding Rosen, J., Sancheti, P., Fierlinger, A. et al. Adv Ther (2016) 33: 998. doi:10.1007/s12325-016-0331-8.

Authors:  William Daley
Journal:  Adv Ther       Date:  2016-10-24       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.